Observational study in patients with HR + and Her2- metastatic breast cancer treated with abemaciclib in the NPU (Compassionate Use Program) program in Spain. ABEMUSS study. 2018-8023
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: LILLY, SA
- Execution start: 18/04/2020
- End of execution: 30/06/2020
- IP: ISABEL BLANCAS LOPEZ-BARAJAS